- Home
- CRGX vs NDMO Comparison
CRGX vs NDMO Comparison
Compare CRGX & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRGX
- NDMO
- Stock Information
- Founded
- CRGX 2021
- NDMO 2019
- Country
- CRGX United States
- NDMO United States
- Employees
- CRGX N/A
- NDMO N/A
- Industry
- CRGX
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- CRGX
- NDMO Finance
- Exchange
- CRGX Nasdaq
- NDMO Nasdaq
- Market Cap
- CRGX 621.4M
- NDMO 596.2M
- IPO Year
- CRGX 2023
- NDMO N/A
- Fundamental
- Price
- CRGX $12.17
- NDMO $10.21
- Analyst Decision
- CRGX Strong Buy
- NDMO
- Analyst Count
- CRGX 6
- NDMO 0
- Target Price
- CRGX $31.80
- NDMO N/A
- AVG Volume (30 Days)
- CRGX 294.7K
- NDMO 218.6K
- Earning Date
- CRGX 11-12-2024
- NDMO 01-01-0001
- Dividend Yield
- CRGX N/A
- NDMO 6.75%
- EPS Growth
- CRGX N/A
- NDMO N/A
- EPS
- CRGX N/A
- NDMO N/A
- Revenue
- CRGX N/A
- NDMO N/A
- Revenue This Year
- CRGX N/A
- NDMO N/A
- Revenue Next Year
- CRGX N/A
- NDMO N/A
- P/E Ratio
- CRGX N/A
- NDMO N/A
- Revenue Growth
- CRGX N/A
- NDMO N/A
- 52 Week Low
- CRGX $11.06
- NDMO $8.99
- 52 Week High
- CRGX $33.92
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- CRGX 36.18
- NDMO 47.48
- Support Level
- CRGX $10.91
- NDMO $10.08
- Resistance Level
- CRGX $15.75
- NDMO $10.25
- Average True Range (ATR)
- CRGX 1.16
- NDMO 0.11
- MACD
- CRGX -0.18
- NDMO 0.04
- Stochastic Oscillator
- CRGX 19.51
- NDMO 94.00
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. The investment objective of the Fund is to seek total return through income exempt from regular federal income taxes and capital appreciation.